Galmed Pharmaceuticals (GLMD)
(Delayed Data from NSDQ)
$0.39 USD
-0.01 (-1.88%)
Updated Apr 25, 2024 03:57 PM ET
After-Market: $0.39 0.00 (-0.64%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Galmed Pharmaceuticals Ltd. [GLMD]
Reports for Purchase
Showing records 121 - 140 ( 192 total )
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - NASH Weekly Newsletter: EASL Preview Calendar
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Strong Presence at EASL Ahead of ARREST Results in June; Affirm Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - NASH Weekly Newsletter: Kick off EASL with NASH BASH Investor Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
NASH Weekly Newsletter: Launch of Our Monthly Clinicaltrials.gov Tracker
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
ARRIVE Versus ARREST Not the Same as Tomatoes or "Tomatos"
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
ARRIVE Sell Off Way Overdone; No Impact on ARREST Thesis; Removing HIV From Model; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Don''t Jump to Conclusions Too Quickly; Reasons Why ARRIVE Failed
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Imminent Data Catalyst: Aramchol Is Set to ARRIVE for NASH; Raising PT to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare: NASH Weekly Newsletter: Oui, Oui, Race to Getting Into EASL Late Breaker
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - NASH Weekly: Our Best Ideas For 2018 In the NASH Space
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - NASH Weekly Newsletter: Who in the NASH Space Had The Best And Worst Year
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare -NASH Weekly: If You Love NASH, You''ll Love What''s to Come at JPM Healthcare
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare -Takeaways from Our Expert Call with NASH Expert, Dr. Stephen Harrison
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - NASH Is Hot and Getting Hotter! Dial-in to NASH Expert on Dec. 4, at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y